Efficacy of live, attenuated, human rotavirus vaccine 89–12 in infants: a randomised placebo-controlled trial
Authors:
- David I BernsteinDBDavid I Bernstein
- David A SackDSDavid A Sack
- Edward RothsteinEREdward Rothstein
- Keith ReisingerKRKeith Reisinger
- Vicki E SmithVSVicki E Smith
- Donna O'SUllivanDODonna O'SUllivan
- Dale R SpriggsDSDale R Spriggs
- Richard L WardRWRichard L Ward
- 1 July 1999
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 354 (9175) , 287-290
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The Protective Effectiveness of Natural Rotavirus Infection in an American Indian PopulationThe Journal of Infectious Diseases, 1998
- Cost-effectiveness Analysis of a Rotavirus Immunization Program for the United StatesJAMA, 1998
- Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12Vaccine, 1998
- Rotavirus vaccines at the thresholdNature Medicine, 1997
- Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritisThe Lancet, 1997
- Rotavirus Infection in Infants as Protection against Subsequent InfectionsNew England Journal of Medicine, 1996
- Mechanisms Of Protection Against Rotavirus In Humans And MiceThe Journal of Infectious Diseases, 1996
- Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US ChildrenJAMA, 1995
- Protection against Rotavirus Disease after Natural Rotavirus InfectionThe Journal of Infectious Diseases, 1994
- Development of an improved method for measuring neutralizing antibody to rotavirusJournal of Virological Methods, 1991